Q3 2025 Nano-X Imaging Ltd Earnings Call Transcript
Key Points
- Nano X Imaging Ltd (NNOX) is expanding its global footprint with new agreements in the Czech Republic and France, enhancing its presence in Europe.
- The company is progressing towards deploying 100 systems worldwide by the end of 2025, with several systems pending regulatory approval.
- Nano X Imaging Ltd (NNOX) is launching its next-generation platform, the Nanox.ARC X system, which features a smaller footprint and simplified installation process.
- The acquisition of VasoHealthcare IT is expected to create synergies and accelerate the deployment of Nanox.AI solutions across US healthcare facilities.
- The company is projecting a minimum of $35 million in revenue for 2026, indicating strong growth expectations.
- Nano X Imaging Ltd (NNOX) reported a GAAP net loss of $13.7 million for the third quarter of 2025, slightly higher than the previous year's loss.
- The company's revenue from AI solutions decreased compared to the previous period, indicating challenges in this segment.
- Regulatory progress outside the US is slower than desired, affecting the company's global deployment plans.
- The company faces challenges in achieving profitability, with expectations to reach EBITDA breakeven on a quarterly basis only by 2027.
- Operational expenses, particularly in sales and marketing, are expected to increase as the company invests in deployment efforts.
Good day and thank you for standing by. Welcome to Nanox's third-quarter 2025 earnings conference call. (Operator Instructions) Please note today's conference is being recorded.
I will now hand a conference over to your speaker host, Mike Cavanaugh of Investor Relations. Please go ahead.
Good morning, and welcome to the Nanox Imaging third-quarter 2025 investor call. Earlier today, Nanox Imaging Limited released financial results for the quarter ending September 30, 2025. The release is currently available on the Investors section of the company's website.
With me today are Erez Meltzer, Chief Executive Officer and Acting Chairman; and Ran Daniel, Chief Financial Officer.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing and commercialization activities, regulatory process and clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
